6RSS

Solution structure of the fourth WW domain of WWP2 with GB1-tag


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 100 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Smad7 Binds Differently to Individual and Tandem WW3 and WW4 Domains of WWP2 Ubiquitin Ligase Isoforms.

Wahl, L.C.Watt, J.E.Yim, H.T.T.De Bourcier, D.Tolchard, J.Soond, S.M.Blumenschein, T.M.A.Chantry, A.

(2019) Int J Mol Sci 20: --

  • DOI: 10.3390/ijms20194682

  • PubMed Abstract: 
  • WWP2 is an E3 ubiquitin ligase that differentially regulates the contextual tumour suppressor/progressor TGFβ signalling pathway by alternate isoform expression. WWP2 isoforms select signal transducer Smad2/3 or inhibitor Smad7 substrates for degrada ...

    WWP2 is an E3 ubiquitin ligase that differentially regulates the contextual tumour suppressor/progressor TGFβ signalling pathway by alternate isoform expression. WWP2 isoforms select signal transducer Smad2/3 or inhibitor Smad7 substrates for degradation through different compositions of protein-protein interaction WW domains. The WW4 domain-containing WWP2-C induces Smad7 turnover in vivo and positively regulates the metastatic epithelial-mesenchymal transition programme. This activity and the overexpression of these isoforms in human cancers make them candidates for therapeutic intervention. Here, we use NMR spectroscopy to solve the solution structure of the WWP2 WW4 domain and observe the binding characteristics of Smad7 substrate peptide. We also reveal that WW4 has an enhanced affinity for a Smad7 peptide phosphorylated at serine 206 adjacent to the PPxY motif. Using the same approach, we show that the WW3 domain also binds Smad7 and has significantly enhanced Smad7 binding affinity when expressed in tandem with the WW4 domain. Furthermore, and relevant to these biophysical findings, we present evidence for a novel WWP2 isoform (WWP2C-ΔHECT) comprising WW3-WW4 tandem domains and a truncated HECT domain that can inhibit TGFβ signalling pathway activity, providing a further layer of complexity and feedback to the WWP2 regulatory apparatus. Collectively, our data reveal a structural platform for Smad substrate selection by WWP2 isoform WW domains that may be significant in the context of WWP2 isoform switching linked to tumorigenesis.


    Organizational Affiliation

    School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK. lloyd.wahl@cityu.edu.hk.,School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK. tiffany.yim228@yahoo.co.uk.,School of Chemistry, University of East Anglia, Norwich NR4 7TJ, UK. t.blumenschein@uea.ac.uk.,School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK. Jessica.Watt@newcastle.ac.uk.,School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK. surinder.soond@yandex.ru.,School of Chemistry, University of East Anglia, Norwich NR4 7TJ, UK. danielle.debourcier@awe.co.uk.,School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK. a.chantry@uea.ac.uk.,School of Chemistry, University of East Anglia, Norwich NR4 7TJ, UK. tolchard@ebi.ac.uk.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
NEDD4-like E3 ubiquitin-protein ligase WWP2
A
109Homo sapiensMutation(s): 0 
Gene Names: WWP2
EC: 2.3.2.26
Find proteins for O00308 (Homo sapiens)
Go to Gene View: WWP2
Go to UniProtKB:  O00308
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 100 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Other privateUnited Kingdom--
Other privateUnited Kingdom--
Other privateUnited Kingdom--
Other privateUnited Kingdom--

Revision History 

  • Version 1.0: 2019-10-09
    Type: Initial release